Declaration of Voting Results & Voting Rights Announcements • Feb 12, 2015
Declaration of Voting Results & Voting Rights Announcements
Open in ViewerOpens in native device viewer
Louvain-la-Neuve, Belgium, February 12, 2015 – IBA (Ion Beam Applications SA, EURONEXT), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received today a transparency notification, in accordance with Article 29 §1 al.2 of the Transparency Law (law of May 2, 2007 and Royal Decree of February 14, 2008) and the content of which is summarized below.
During the year 2014, Sopartec SA has sold IBA shares with voting rights, so that as from 12 June 2014, Sopartec SA held 403 049 IBA shares with voting rights. As a result, the sum of the affiliated companies Sopartec SA and Catholic University of Louvain (UCL) has been brought below the 3% threshold provided in Article 34 of IBA's Articles of Association.
| ENTITY | 31 DECEMBER 2013 | 12 JUNE 2014 | ||
|---|---|---|---|---|
| DENOMINATOR 27 635 439 |
DENOMINATOR 27 675 955 |
|||
| SHARES WITH |
% | SHARES WITH |
% | |
| VOTING RIGHTS | VOTING RIGHTS | |||
| Sopartec SA | 529 925 | 1.92% | 403 049 | 1.446% |
| Place de l'Université 1 | ||||
| 1348 Louvain-la-Neuve | ||||
| UCL | 426 885 | 1.94% | 426 885 | 1.542% |
| Place de l'Université 1 | ||||
| 1348 Louvain-la-Neuve | ||||
| Total | 956 810 | 3.46% | 829 934 | 2.998% |
* * * *
IBA (Ion Beam Applications SA) is a cancer diagnostics and treatment equipment company, and the worldwide technology leader in the field of proton therapy, the most advanced form of radiotherapy available today.
The Company's primary expertise lies in the development of next generation proton therapy technologies that provide oncology care providers with premium quality services and equipment. IBA's proton therapy solutions are scalable and adaptable, offering universal full scale proton therapy centers as well as next generation compact, single room solutions. IBA also focuses on the development and supply of dosimetry solutions for Quality Assurance of medical equipment and increased patient safety as well as particle accelerators for medical and industrial applications.
IBA employs more than 1,000 people worldwide and is listed on Euronext Brussels, (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB), more information can be found at: www.iba-worldwide.com
Press release | February 12, 2015 1 | 2
Regulated information
Jean-Marc Bothy Chief Financial Officer Tel: +32 10 47 58 90 [email protected] Thomas Ralet Vice-President Corporate Communication Tel : +32 10 47 58 90 [email protected]
Press release | February 12, 2015 2 | 2
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.